1. Home
  2. COGT vs NTST Comparison

COGT vs NTST Comparison

Compare COGT & NTST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COGT
  • NTST
  • Stock Information
  • Founded
  • COGT 2014
  • NTST 2019
  • Country
  • COGT United States
  • NTST United States
  • Employees
  • COGT N/A
  • NTST N/A
  • Industry
  • COGT Biotechnology: Pharmaceutical Preparations
  • NTST Real Estate Investment Trusts
  • Sector
  • COGT Health Care
  • NTST Real Estate
  • Exchange
  • COGT Nasdaq
  • NTST Nasdaq
  • Market Cap
  • COGT 1.0B
  • NTST 1.2B
  • IPO Year
  • COGT 2018
  • NTST 2020
  • Fundamental
  • Price
  • COGT $6.48
  • NTST $15.85
  • Analyst Decision
  • COGT Buy
  • NTST Strong Buy
  • Analyst Count
  • COGT 7
  • NTST 7
  • Target Price
  • COGT $14.17
  • NTST $17.75
  • AVG Volume (30 Days)
  • COGT 1.0M
  • NTST 865.3K
  • Earning Date
  • COGT 05-06-2025
  • NTST 04-28-2025
  • Dividend Yield
  • COGT N/A
  • NTST 5.30%
  • EPS Growth
  • COGT N/A
  • NTST N/A
  • EPS
  • COGT N/A
  • NTST N/A
  • Revenue
  • COGT N/A
  • NTST $162,784,000.00
  • Revenue This Year
  • COGT N/A
  • NTST $10.40
  • Revenue Next Year
  • COGT N/A
  • NTST $9.61
  • P/E Ratio
  • COGT N/A
  • NTST N/A
  • Revenue Growth
  • COGT N/A
  • NTST 23.41
  • 52 Week Low
  • COGT $5.88
  • NTST $13.42
  • 52 Week High
  • COGT $12.61
  • NTST $18.97
  • Technical
  • Relative Strength Index (RSI)
  • COGT 38.02
  • NTST 68.82
  • Support Level
  • COGT $6.31
  • NTST $15.24
  • Resistance Level
  • COGT $7.49
  • NTST $15.45
  • Average True Range (ATR)
  • COGT 0.43
  • NTST 0.32
  • MACD
  • COGT -0.04
  • NTST 0.03
  • Stochastic Oscillator
  • COGT 10.90
  • NTST 96.30

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.

About NTST NetSTREIT Corp.

Netstreit Corp is an internally managed real estate investment trust. The company acquires, owns, and manages single-tenant, retail commercial real estate subject to long-term net leases with high-credit quality tenants across the United States. It focuses on tenants in industries where a physical location is critical to the generation of sales and profits, with a focus on necessity goods and essential services in the retail sector, including home improvement, auto parts, drug stores and pharmacies, general retail, grocers, convenience stores, discount stores, and quick-service restaurants. Majorily operates in U.S. States and Other counties, and derives maximum of revenue from USA.

Share on Social Networks: